INO beat EPS expectations by 116.60%
Mar 16, 2026, 10:32 AM
0.00%
What does INO do
Inovio Pharmaceuticals, based in San Diego, develops DNA medicines targeting infectious diseases, cancer, and HPV-related conditions, with key candidates including INO-3107 for recurrent respiratory papillomatosis. The company employs 122 people and utilizes CELLECTRA devices for DNA delivery.
Inovio Pharmaceuticals (INO) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Inovio Pharmaceuticals's actual EPS was $0.06, beating the estimate of -$0.36 per share, resulting in a 116.60% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.